Australia's most trusted
source of pharma news
Saturday, 06 September 2025
Posted 27 January 2017
Johnson & Johnson has agreed to buy Actelion, Europe's biggest biotech company, for $US30 billion in a deal that will spin off the target's R&D arm.
The deal will help the US giant deal with the loss of exclusivity on Remicade (infliximab) by delivering a range of already successful treatments for conditions such as pulmonary arterial hypertension that are expected to boost sales by more than $US2 billion annually.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.